Article | April 19, 2023

Why Adaptive Trial Designs Require Adaptable Technology

Source: Mednet
GettyImages-1137422767 adaptive trial

In The Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry, the FDA defines adaptive clinical trial designs as, “a clinical trial design that allows for prospectively planned modifications to one or more aspects of the design based on accumulating data from subjects in the trial.”

The adaptive trial approach has been reported to reduce potential costs by creating greater upfront flexibility and comparing more treatments, providing insights for earlier decisions. High failure rates and increasing costs have driven the industry toward adaptive trial designs recently, among the design’s attractive benefits. By operating under an adaptive trial design, researchers can determine whether to stop the trial earlier, drop treatments or dosage early and test more treatments simultaneously. At the same time, patients are more likely to participate and stay engaged when they believe there is a greater probability of getting the best treatment.

While the study design is growing more popular for its ability to prospectively plan modifications, adaptive trials tend to require versatile technology to support their complex and ever-changing nature.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader